Renaissance Technologies’s Curanex Pharmaceuticals CURX Stock Holding History

Renaissance Technologies’s Portfolio CURX Stock Details CURX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-59,297	Closed	-$19.6K	–	3801
2025 Q4	$19.6K	Buy	+59,297	New	+$32.6K	﹤0.01%	3148

Other funds holding CURX

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies's CURX Position: Q1 2026 in Review

Renaissance Technologies sold out of Curanex Pharmaceuticals (CURX) in Q1 2026, closing a stake of 59,297 shares — an estimated $19.6K sold.

Renaissance Technologies first reported a position in CURX in Q4 2025 and held it in 1 quarter. The position peaked at $19.6K in Q4 2025. 8 funds tracked by Wall St. Rank hold CURX as of Q1 2026.

Renaissance Technologies reported no remaining Curanex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Renaissance Technologies sold 59,297 Curanex Pharmaceuticals shares in Q1 2026, an estimated $19.6K.
Renaissance Technologies first reported a position in Curanex Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Renaissance Technologies's Curanex Pharmaceuticals position peaked at $19.6K in Q4 2025.
8 funds tracked by Wall St. Rank held Curanex Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.